Roche Holding AG
SIX:ROG
Roche Holding AG
Cash & Cash Equivalents
Roche Holding AG
Cash & Cash Equivalents Peer Comparison
Competitive Cash & Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Roche Holding AG
SIX:ROG
|
Cash & Cash Equivalents
CHf5.4B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
3%
|
|
Novartis AG
SIX:NOVN
|
Cash & Cash Equivalents
$9.5B
|
CAGR 3-Years
36%
|
CAGR 5-Years
7%
|
CAGR 10-Years
2%
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Cash & Cash Equivalents
$9m
|
CAGR 3-Years
244%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Cash & Cash Equivalents
$74m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Roche Holding AG's Cash & Cash Equivalents?
Cash & Cash Equivalents
5.4B
CHF
Based on the financial report for Dec 31, 2023, Roche Holding AG's Cash & Cash Equivalents amounts to 5.4B CHF.
What is Roche Holding AG's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
3%
Over the last year, the Cash & Cash Equivalents growth was 8%. The average annual Cash & Cash Equivalents growth rates for Roche Holding AG have been -2% over the past three years , -4% over the past five years , and 3% over the past ten years .